Changing trends in cytomegalovirus disease in HIV-infected patients

Herpes

Volumn 8, Issue 2, 2001, Pages 37-40

  Deayton, J R ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cytomegalovirus (CMV); Highly active antiretroviral therapy (HAART); Immune reconstitution; Retinitis

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CIDOFOVIR; FOSCARNET; GANCICLOVIR;

ARTICLE; CHEMOPROPHYLAXIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG INDICATION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INFECTION PREVENTION; INFECTION RISK; PRIORITY JOURNAL; RISK MANAGEMENT;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HIV INFECTIONS; HUMANS; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034946528     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus
2. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease
3. Development of cytomegalovirus disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test
4. Utility of urine and leukocyte culture and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for human cytomegalovirus disease
5. Survival of patients with the acquired immune deficiency syndrome after the development of cytomegalovirus retinopathy
6. Treatment of cytomegalovirus retinitis in patients with the acquired immune deficiency syndrome
7. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
8. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy
9. Recurrence of CMV viraemia and development of anti-CMV drug resistance in patients receiving highly active antiretroviral therapy after CMV retinitis
10. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
11. 6 cells/l following combination antiretroviral therapy including protease inhibitors
12. Cytomegalovirus disease in HIV-infected patients heated with protease inhibitors
13. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis
14. Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS
15. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors
16. Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease
17. Cytomegalovirus retinitis in HIV-infected patients with and without highly active antiretroviral therapy
18. Cytomegalovirus retinitis aider the initiation of highly active antiretroviral therapy: A 2 year prospective study
19. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy
20. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS
21. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy
22. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
23. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
24. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
25. Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end-organ disease
26. Early immune reconstitution and the control of cytomegalovirus replication following highly active antiretroviral therapy
27. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: A new syndrome
28. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis
29. Cystoid macular edema associated with patients with the acquired immunodeficiency syndrome
30. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease
31. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients
32. Evidence that HAART induced immune recovery vitritis in CMV retinitis patients is immune mediated
33. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
34. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy
35. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy
36. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy
37. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients
38. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts
39. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy
40. Discontinuing anticytomegalovirus therapy in patients with immune restoration after combination antiretroviral therapy
41. Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy
42. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis
43. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy
44. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the ere of highly active antiretroviral therapy
45. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy
46. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy